ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Revenue
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H had a revenue of 44.01M in the quarter ending Jun 30, 2025, with -44.16%. This bring the company's revenue in the last twelve months to 122.83M, Decreased 54.43%. In the fiscal year ending Dec 31, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H had annual revenue of 74.15M with 19109.59% growth.